Molecular targeting for treatment of human T-lymphotropic virus type 1 infection

Soltani, A. and Hashemy, S. I. and Zahedi Avval, F. and Soleimani, A. and Rafatpanah, H. and Rezaee, S. A. and Griffith, R. and Mashkani, B. (2019) Molecular targeting for treatment of human T-lymphotropic virus type 1 infection. Biomedicine and Pharmacotherapy, 109. pp. 770-778.

[img] Text
Molecular targeting for treatment of human.pdf

Download (1MB)


Human T-cell lymphotropic virus type 1 (HTLV-1) infection is linked to adult T-cell leukemia-lymphoma (ATLL) and HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and several other disorders. ATLL occurs in approximately 5 of the 15–20 million people infected by HTLV-1 in the world. In general, ATLL is resistant to chemotherapy, which underlines the need for new and effective therapeutic strategies. Previous studies highlighted the role of viral enzymes, responsible for viral replication, and regulatory proteins such as Tax and HBZ in the progression of HTLV-1-associated diseases. There are conflicting reports on the efficacy of current enzyme inhibitors, mainly developed against human immunodeficiency virus (HIV), for treatment of HTLV-1 infection. New treatment approaches including monoclonal antibodies show promising results and exert significant cytotoxic effects on ATLL cells. This manuscript reviews the recent developments in molecular targeting for treatment of HTLV-1 infection. © 2018 Elsevier Masson SAS

Item Type: Article
Additional Information: Cited By :1 Export Date: 16 February 2020 CODEN: BIPHE Correspondence Address: Mashkani, B.; Surgical Oncology Research Center, School of Medicine, Mashhad University of Medical SciencesIran; email:
Uncontrolled Keywords: Adult T-cell leukemia-lymphoma (ATLL) Antiviral therapy Human T-cell lymphotropic virus 1 (HTLV-1) Integrase Protease Reverse transcriptase antivirus agent bortezomib cell protein histone deacetylase inhibitor monoclonal antibody regulator protein survivin Tax protein enzyme inhibitor DNA replication HTLV-1 infection human Human immunodeficiency virus Human T-lymphotropic virus 1 priority journal protein targeting Review spinal cord disease structural gene tropical spastic paraparesis virus envelope virus replication virus typing amino acid sequence animal chemistry genetics molecularly targeted therapy procedures protein secondary structure treatment outcome trends Animals Antibodies, Monoclonal Enzyme Inhibitors HTLV-I Infections Humans Molecular Targeted Therapy Protein Structure, Secondary
Subjects: QV pharmacology
Divisions: Mashhad University of Medical Sciences
Depositing User: mr lib1 lib1
Date Deposited: 27 Jun 2020 05:59
Last Modified: 27 Jun 2020 05:59

Actions (login required)

View Item View Item